Daily Respiratory Research Analysis
Three impactful respiratory studies stand out today: identification of MFSD6 as a functional entry receptor for EV-D68 with a decoy protein that protects newborn mice; evidence that Omicron SARS-CoV-2 variants have evolved greater upper respiratory tract fitness without severe lung pathology; and mechanistic data linking endothelial fatty acid metabolism (Cpt1a) to suppression of EndoMT and vascular remodeling in neonatal hyperoxia models of BPD-associated pulmonary hypertension.
Summary
Three impactful respiratory studies stand out today: identification of MFSD6 as a functional entry receptor for EV-D68 with a decoy protein that protects newborn mice; evidence that Omicron SARS-CoV-2 variants have evolved greater upper respiratory tract fitness without severe lung pathology; and mechanistic data linking endothelial fatty acid metabolism (Cpt1a) to suppression of EndoMT and vascular remodeling in neonatal hyperoxia models of BPD-associated pulmonary hypertension.
Research Themes
- Viral entry mechanisms and antiviral decoy strategies
- SARS-CoV-2 variant pathogenesis and respiratory tract tropism
- Endothelial metabolism and pulmonary vascular remodeling in neonatal lung injury
Selected Articles
1. MFSD6 is an entry receptor for respiratory enterovirus D68.
The authors identify MFSD6 as a functional EV-D68 entry receptor that mediates viral attachment. An MFSD6-Fc recombinant decoy blocks uptake and infection in vitro and protects newborn mice from lethal challenge, highlighting a druggable entry mechanism.
Impact: This is the first demonstration of MFSD6 as an EV-D68 entry factor with a translational decoy strategy that prevents lethality in vivo, opening avenues for antivirals against a major pediatric respiratory pathogen.
Clinical Implications: Entry-blocking biologics such as MFSD6-Fc could be developed for prophylaxis or early treatment of EV-D68 outbreaks, especially in pediatric populations at risk for severe respiratory disease and acute flaccid myelitis.
Key Findings
- MFSD6 is necessary for EV-D68 attachment and supports viral replication.
- The second extracellular domain of MFSD6 mediates EV-D68 recognition.
- An MFSD6-Fc ectodomain decoy potently inhibits EV-D68 uptake and infection in vitro.
- MFSD6-Fc prevents lethality in EV-D68–challenged newborn mice.
Methodological Strengths
- Mechanistic mapping of receptor function including domain-level recognition.
- Translational validation with a recombinant decoy in both cell culture and an in vivo neonatal mouse model.
Limitations
- Preclinical study without human clinical validation.
- Breadth across EV-D68 clades and potential resistance pathways were not fully explored.
Future Directions: Validate MFSD6 dependency and MFSD6-Fc efficacy across EV-D68 clades, assess safety/pharmacokinetics, and explore synergy with neutralizing antibodies or small-molecule capsid binders.
Enterovirus D68 (EV-D68) is a leading non-polio enterovirus that causes severe respiratory diseases and poliomyelitis-like illness in children. Viral entry represents a potential multifaceted target for antiviral intervention; however, there are no approved inhibitors to block EV-D68. Here, we identify the functionally undescribed membrane protein major facilitator superfamily-domain-containing protein 6 (MFSD6) as an EV-D68 entry factor amenable to therapeutic intervention. Specifically, MFSD6 expression is crucial for EV-D68 replication. MFSD6 binds to EV-D68 particles and is necessary for virus attachment to cells. The second extracellular domain of the MFSD6 molecule is involved in the recognition of EV-D68. On the basis of these findings, we engineered a recombinant protein complex comprising the MFSD6 ectodomain fused to Fc (MFSD6-Fc(CH3)), which potently inhibited EV-D68 uptake. MFSD6-Fc(CH3) effectively blocked EV-D68 infection in vitro and prevented lethality in newborn mice. In conclusion, our study not only identifies MFSD6 as an EV-D68 entry factor but also reveals a potential antiviral target and therapeutic agent.
2. Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology.
Contemporary Omicron variants show enhanced upper respiratory tract replication with limited lung pathology across animal and primary human cell models. JN.1 is further attenuated and failed to transmit in male hamsters, indicating continued evolution toward URT fitness.
Impact: Defines variant-specific respiratory tract tropism and transmissibility using cross-model comparisons, informing risk assessment and public health strategies for future Omicron sublineages.
Clinical Implications: URT-focused infection with limited lung involvement supports prioritizing interventions that target upper airway transmission (e.g., nasal vaccines, ventilation/filtration), while surveillance should monitor attenuation and transmissibility shifts.
Key Findings
- Omicron variants replicate efficiently in the upper respiratory tract with limited lung pathology.
- Variants fail to replicate in human lung organoids but infect primary human nasal epithelium.
- JN.1 is attenuated in both URT and LRT and fails to transmit in the male hamster model.
- Cross-model assessment shows evolution favoring URT fitness among Omicron sublineages.
Methodological Strengths
- Use of both animal (Syrian hamster) and primary human airway cell models, including organoids.
- Comparative analysis across multiple contemporary Omicron variants with assessments of transmissibility, antigenicity, and innate responses.
Limitations
- Hamster model findings may not fully extrapolate to humans, and sex-specific transmission differences were not fully explored.
- Does not evaluate impacts of pre-existing human immunity or vaccination on variant tropism and transmission.
Future Directions: Integrate host immunity contexts (prior infection/vaccination) into transmission models, assess URT-targeted vaccines, and monitor emerging sublineages for reversions toward LRT tropism.
The emergence of the Omicron lineage represented a major genetic drift in SARS-CoV-2 evolution. This was associated with phenotypic changes including evasion of pre-existing immunity and decreased disease severity. Continuous evolution within the Omicron lineage raised concerns of potential increased transmissibility and/or disease severity. To address this, we evaluate the fitness and pathogenesis of contemporary Omicron variants XBB.1.5, XBB.1.16, EG.5.1, and JN.1 in the upper (URT) and lower respiratory tract (LRT). We compare in vivo infection in Syrian hamsters with infection in primary human nasal and lung epithelium cells and assess differences in transmissibility, antigenicity, and innate immune activation. Omicron variants replicate efficiently in the URT but display limited pathology in the lungs compared to previous variants and fail to replicate in human lung organoids. JN.1 is attenuated in both URT and LRT compared to other Omicron variants and fails to transmit in the male hamster model. Our data demonstrate that Omicron lineage evolution has favored increased fitness in the URT.
3. Endothelial Cpt1a Inhibits Neonatal Hyperoxia-Induced Pulmonary Vascular Remodeling by Repressing Endothelial-Mesenchymal Transition.
Using endothelial-specific Cpt1a knockout neonatal mice exposed to hyperoxia, the study shows that endothelial Cpt1a suppresses EndoMT and thereby limits pulmonary vascular remodeling pertinent to BPD-associated pulmonary hypertension.
Impact: Reveals a metabolic-endothelial mechanism linking fatty acid transport/oxidation to EndoMT and vascular remodeling in neonatal lung injury, suggesting a druggable pathway in BPD-associated pulmonary hypertension.
Clinical Implications: Therapeutic strategies that enhance endothelial Cpt1a activity or modulate fatty acid oxidation may prevent pulmonary vascular remodeling in preterm infants with BPD at risk for pulmonary hypertension.
Key Findings
- Endothelial Cpt1a expression is reduced in a rodent BPD model.
- Endothelial-specific Cpt1a knockout in neonatal mice exposed to hyperoxia promotes pulmonary vascular remodeling.
- Cpt1a restrains endothelial-mesenchymal transition (EndoMT), linking endothelial fatty acid metabolism to vascular remodeling.
Methodological Strengths
- Endothelial cell-specific genetic knockout model in neonatal hyperoxia.
- Mechanistic linkage between metabolic enzyme activity and EndoMT in vivo.
Limitations
- Rodent neonatal hyperoxia may not fully recapitulate human BPD pathophysiology.
- Therapeutic modulation of Cpt1a was not tested in clinically relevant interventions.
Future Directions: Assess pharmacologic or gene therapy approaches to augment endothelial Cpt1a/FAO in neonatal lung injury models and evaluate downstream EndoMT signaling nodes as co-targets.
Pulmonary hypertension (PH) increases the mortality of preterm infants with bronchopulmonary dysplasia (BPD). There are no curative therapies for this disease. Lung endothelial carnitine palmitoyltransferase 1a (Cpt1a), the rate-limiting enzyme of the carnitine shuttle system, is reduced in a rodent model of BPD. It is unknown whether endothelial Cpt1a reduction causes pulmonary vascular (PV) remodeling. The latter can be the result of endothelial-mesenchymal transition (EndoMT). Here, endothelial cell (EC)-specific Cpt1a KO and WT mice (<12 h old) are exposed to hyperoxia (70% O